SM-31900, a novel NMDA receptor glycine-binding site antagonist, reduces infarct volume induced by permanent middle cerebral artery occlusion in spontaneously hypertensive rats

Neurochemistry International

Volumn 42, Issue 5, 2003, Pages 375-384

  Ohtani, Ken ichi ^a   Tanaka, Hiroyasu ^a   Ohno, Yukihiro ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antagonist; Glycine binding site; Ischemia; Neuroprotective; NMDA receptor; SM 31900

Indexed keywords

GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SM 31900; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BRAIN INFARCTION; CONTROLLED STUDY; DISEASE MODEL; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; ELECTROCOAGULATION; ESSENTIAL HYPERTENSION; ISCHEMIA; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; OLFACTORY TRACT; PRIORITY JOURNAL; RAT; STEADY STATE; STROKE; TIME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; INFARCTION, MIDDLE CEREBRAL ARTERY; LIGATION; MALE; MIDDLE CEREBRAL ARTERY; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; SPECIES SPECIFICITY;

ANIMALIA; EMBRYOPHYTA;

EID: 0037375749     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(02)00137-7     Document Type: Article

References (67)

1. Albers G.W., Clark W.M., Atkinson R.P., Madden K., Data J.L., Whitehouse M.J. Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke. 30:1999;508-513.
2. Baker A.J., Zornow M.H., Scheller M.S., Yaksh T.L., Skilling S.R., Smullin D.H., Larson A.A., Kuczenski R. Changes in extracellular concentrations of glutamate, aspartate, glycine, dopamine, serotonin, and dopamine metabolites after transient global ischemia in the rabbit brain. J. Neurochem. 57:1991;1370-1379.
3. Bordi F., Pietra C., Ziviani L., Reggiani A. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduced the infarct area in the MCAo model of focal ischemia in the rat. Exp. Neurol. 145:1997;425-433.
4. Bordi F., Terron A., Reggiani A. The neuroprotective glycine receptor antagonist GV150526 does not produce neuronal vacuolization or cognitive deficits in rats. Eur. J. Pharmacol. 378:1999;153-160.
5. Brint S., Jacewicz M., Kiessling M., Tanabe J., Pulsinelli W. Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. J. Cereb. Blood Flow Metab. 8:1988;474-485.
6. Buchan A.M., Slivka A., Xue D. The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke. Brain Res. 574:1992;171-177.
7. Castillo J., Dávalos A., Noya M. Progression of ischemic stroke and excitotoxic aminoacids. Lancet. 349:1997;79-83.
8. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988a;623-634.
9. Choi D.W. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11:1988b;465-469.
10. Choi D.W. Calcium: still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 18:1995;58-60.
11. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13:1990;171-182.
12. Choi D.W., Koh J.Y., Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J. Neurosci. 8:1988;185-196.
13. Ciabarra A.M., Sullivan J.M., Gahn L.G., Pecht G., Heinemann S., Sevarino K.A. Cloning and characterization of χ-1: A developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J. Neurosci. 15:1995;6498-6508.
14. Coyle P. Different susceptibilities to cerebral infarction in spontaneously hypertensive (SHR) and normotensive Sprague-Dawley rats. Stroke. 17:1986;520-525.
15. Danysz W., Parsons C.G. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50:1998;597-664.
16. Dirnagl U., Tanabe J., Pulsinelli W. Pre- and post-treatment with MK-801 but not pretreatment alone reduces neocortical damage after focal cerebral ischemia in the rat. Brain Res. 527:1990;62-68.
17. Duverger D., MacKenzie E.T. The quantification of cerebral infarction following focal ischemia in the rat: influence of strain, arterial pressure, blood glucose concentration, and age. J. Cereb. Blood Flow Metab. 8:1988;449-461.
18. Dyker A.G., Lees K.R. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Stroke. 30:1999;986-992.
19. Fix A.S., Horn J.W., Wightman K.A., Johnson C.A., Long G.G., Storts R.W., Farber N., Wozniak D.F., Olney J.W. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123:1993;204-215.
20. Gill R., Foster A.C., Woodruff G.N. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. 7:1987;3343-3349.
21. Ginsberg M.D., Busto R. Rodent models of cerebral ischemia. Stroke. 20:1989;1627-1642.
22. Globus M.Y.-T., Ginsberg M.D., Busto R. Excitotoxic index - a biochemical marker of selective vulnerability. Neurosci. Lett. 127:1991;39-42.
23. Grotta J., Clark W., Coull B., Pettigrew L.C., Mackay B., Goldstein L.B., Meissner I., Murphy D., LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke. 26:1995;602-605.
24. Hargreaves R.J., Rigby M., Smith D., Hill R.G. Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br. J. Pharmacol. 110:1993a;36-42.
25. Hargreaves R.J., Rigby M., Smith D., Hill R.G., Iversen L.L. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem. Res. 18:1993b;1263-1269.
26. Hawkinson J.E., Huber K.R., Sahota P.S., Han Hsu H., Weber E., Whitehouse M.J. The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA 1021 does not produce pathological changes in rat brain. Brain Res. 744:1997;227-234.
27. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531.
28. Katayama, S., Ae, N., Tanaka, H., Nagata, R., 2000. Tricyclic indole-2-carboxylic acids, highly in vivo active antagonists for the glycine binding site of the NMDA receptor. In: Proceedings of the 220th Meeting of the American Chemical Society, Washington, DC, pp. 215 (Abstr., Medi).
29. Kleckner N.W., Dingledine R. Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science. 241:1988;835-837.
30. Koek W., Woods J.H., Winger G.D. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produce phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;969-974.
31. Koizumi J., Yoshida Y., Nakazawa T., Ooneda G. Experimental studies of ischemic brain edema. I. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn. J. Stroke. 8:1986;1-8.
32. Kretschmer B.D., Kratzer U., Breithecker K., Koch M. ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats. Eur. J. Pharmacol. 331:1997;109-116.
33. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268:1994;335-345.
34. Lees K.R. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 49:1997;S66-S69.
35. Lees, K.R., Asplund, K., Carolei, A., Davis, S.M., Diener, H.-C., Kaste, M., Orgogozo, J.-M., Whitehead, J., GAIN International Investigators, 2000. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet 355, 1949-1956.
36. MacLeod A.M., Grimwood S., Barton C., Bristow L., Saywell K.L., Marshall G.R., Ball R.G. Identification of 3,5-dihydro-2-aryl-1H-pyrazolo[3,4-c]quinoline-1,4(2H)-diones as novel high-affinity glycine site N-methyl-D-aspartate antagonists. J. Med. Chem. 38:1995;2239-2243.
37. Matsumoto K., Graf R., Rosner G., Taguchi J., Heiss W.-D. Elevation of neuroactive substances in the cortex of cats during prolonged focal ischemia. J. Cereb. Blood Flow Metab. 13:1993;586-594.
38. Michaels R.L., Rothman S.M. Glutamate neurotoxicity in vitro: antagonist pharmacology and intracellular calcium concentrations. J. Neurosci. 10:1990;283-292.
39. Morris R.G.M., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist. AP-5. Nature. 319:1986;774-776.
40. Ohtani K., Tanaka H., Yasuda H., Maruoka Y., Kawabe A., Nakamura M. Blocking the glycine-binding site of NMDA receptors prevents the progression of ischemic pathology induced by bilateral carotid artery occlusion (BCAo) in spontaneously hypertensive rats (SHRs). Brain Res. 871:2000;311-318.
41. Ohtani K., Tanaka H., Yoneda Y., Yasuda H., Ito A., Nagata R., Nakamura M. In vitro and in vivo antagonistic activities of SM-31900 for the NMDA receptor glycine-binding site. Brain Res. 944:2002;165-173.
42. Oliff H.S., Weber E., Miyazaki B., Marek P. Infarct volume varies with rat strain and vendor in focal cerebral ischemia induced by transcranial middle cerebral artery occlusion. Brain Res. 699:1995;329-331.
43. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 244:1989;1360-1362.
44. Ozyurt E., Graham D.I., Woodruff G.N., McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J. Cereb. Blood Flow Metab. 8:1988;138-143.
45. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., McCulloch J. Focal cerebral ischemia in the cat: treatment with the glutamate antagonist MK-801 after induction of ischemia. J. Cereb. Blood Flow Metab. 8:1988a;757-762.
46. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann. Neurol. 24:1988b;543-551.
47. Reggiani A., Pietra C., Arban R., Marzola P., Guerrini U., Ziviani L., Boicelli A., Sbarbati A., Osculati F. The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging. Eur. J. Pharmacol. 419:2001;147-153.
48. Rossi D.J., Oshima T., Attwell D. Glutamate release in sever brain ischaemia is mainly by reversed uptake. Nature. 403:2000;316-321.
49. Rothman S.M., Olney J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19:1986;105-111.
50. Roussel S., Pinard E., Seylaz J. Kynurenate dose not reduce infarct size after middle cerebral artery occlusion in spontaneously hypertensive rats. Brain Res. 518:1990;353-355.
51. Roussel S., Pinard E., Seylaz J. Focal cerebral ischemia in chronic hypertension: no protection by R-phenyl-isopropyl-adenosine. Brain Res. 545:1991;171-174.
52. Roussel S., Pinard E., Seylaz J. Effect of MK-801 on focal brain infarction in normotensive and hypertensive rats. Hypertension. 19:1992;40-46.
53. Sacco, R.L., DeRosa, J.T., Haley, E.C., Levin, B., Ordronneau, P., Phillips, S.J., Rundek, T., Snipes, R.G., Thompson, J.L.P., GAIN Americas Investigators, 2001. Glycine antagonist in neuroprotection for patients with acute stroke. JAMA 285, 1719-1728.
54. Siesjö B.K., Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. J. Cereb. Blood Flow Metab. 9:1989;127-140.
55. Simon R.P., Swan J.H., Griffiths T., Meldrum B.S. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science. 226:1984;850-852.
56. Stroke Therapy Academic Industry Roundtable (STAIR), 1999. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752-2758.
57. Sucher N.J., Akbarian S., Chi C.L., Leclerc C.L., Awobuluyi M., Deitcher D.L., Wu M.K., Yuan J.P., Jones E.G., Lipton S.A. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J. Neurosci. 15:1995;6509-6520.
58. Szatkowski M., Attwell D. Triggering and execution of neuronal death in brain ischemia: two phases of glutamate release by different mechanisms. Trends Neurosci. 17:1994;359-365.
59. Takagi K., Ginsberg M.D., Globus M.Y.-T., Dietrich W.D., Martinez E., Kraydieh S., Busto R. Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbral region following middle cerebral artery occlusion in the rat: correlation with histopathology. J. Cereb. Blood Flow Metab. 13:1993;575-585.
60. Takano K., Tatlisumak T., Formato J.E., Carano R.A., Bergmann A.G., Pullan L.M., Bare T.M., Sotak C.H., Fisher M. Glycine site antagonist attenuates infarct size in experimental focal ischemia: postmortem and diffusion mapping studies. Stroke. 28:1997;1255-1263.
61. Takaoka S., Bart R.D., Pearlstein R., Brinkhous A., Warner D.S. Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled. J. Cereb. Blood Flow Metab. 17:1997;161-167.
62. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. Focal cerebral ischemia in the rat. 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1:1981;53-60.
63. Tanaka H., Yasuda H., Kato T., Maruoka Y., Kawabe A., Kawasima C., Ohtani K., Nakamura M. Neuroprotective and anticonvulsant action of SM-18400, a novel strychnine-insensitive glycine site antagonists. J. Cereb. Blood Flow Metab. 15(Suppl. 1):1995;S431.
64. Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C.E., Reis D.J. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature. 363:1993;260-263.
65. Woodward R.M., Huettner J.E., Guastella J., Keana J.F.W., Weber E. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol. Pharmacol. 47:1995;568-581.
66. Yao H., Ginsberg M.D., Watson B.D., Prado R., Dietrich W.D., Kraydieh S., Busto R. Failure of MK-801 to reduce infarct volume in thrombotic middle cerebral artery occlusion in rats. Stroke. 24:1993;864-871.
67. Zea Longa E., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.